BIO Announcement Imminent?
This article was originally published in The Pink Sheet Daily
Executive Summary
Rep. Greenwood is understood to have resigned as chairman of the House Commerce/Oversight Subcommittee. BIO's board meets to discuss selection of a new president.
You may also be interested in...
BIO Top Job May Go To Rep. Greenwood
Oversight Subcommittee chairman confirms he is considering leaving Congress to pursue a new opportunity, but says he will have no further comment until he makes a decision "in the very near future." Greenwood has been among most active legislators on pharmaceutical issues, and has worked with BIO on stem cell and human subject protection proposals.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.
AstraZeneca Joins The $35 Inhaler Club; Medicare Patients Waiting On Congress For Membership
AZ’s move follows Boehringer’s announcement earlier this month and parallels what insulin sponsors did – but almost in reverse. For inhalers, political pressure on out-of-pocket costs has produced copay caps in the commercial market first, not Medicare.